

# STN Columbus

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS EXPRESS	JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 22:22:24 ON 13 MAR 2009

=> file uspatall

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.54	1.54

FILE 'USPATFULL' ENTERED AT 22:26:23 ON 13 MAR 2009  
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 22:26:23 ON 13 MAR 2009  
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 22:26:23 ON 13 MAR 2009  
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s tamsulosin  
L1 1288 TAMSULOSIN

=> s tamsulosin/clm  
L2 226 TAMSULOSIN/CLM

=> s polymer?  
L3 1224605 POLYMER?

=> s polymer?/clm  
L4 432182 POLYMER?/CLM

=> s (calcium or potassium or sodium or magnesium)  
L5 1287207 (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)

=> s (calcium or potassium or sodium or magnesium)/clm  
L6 305082 (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)/CLM

=> s (multilayer or layer)  
L7 2063906 (MULTILAYER OR LAYER)

=> s (multilayer or layer)/clm  
L8 810896 (MULTILAYER OR LAYER)/CLM

=> s capsule?  
L9 243183 CAPSULE?

=> s capsule?/clm  
L10 27197 CAPSULE?/CLM

=> s l1 and l4  
L11 242 L1 AND L4

=> s l1 and l3  
L12 897 L1 AND L3

=> s l5 and l12  
L13 888 L5 AND L12

=> s l7 and l13  
L14 600 L7 AND L13

=> s l9 and l14  
L15 493 L9 AND L14

=> s l2 and l4  
L16 50 L2 AND L4

=> s l6 and l16  
L17 33 L6 AND L16

=> s l8 and l17  
L18 6 L8 AND L17

=> s l10 and l18  
L19 2 L10 AND L18

=> d 1-2

L19 ANSWER 1 OF 2 USPATFULL on STN

Full Text

AN 2009:4272 USPATFULL  
TI Controlled release tamsulosin hydrochloride formulation  
IN Cheng, Xiu Xiu, Weston, FL, UNITED STATES  
Cheng, Xiufang, Weston, FL, UNITED STATES  
PA Watson Pharmaceuticals, Inc. (U.S. corporation)  
PI US 20090004284 A1 20090101  
AI US 2007-821990 A1 20070626 (11)  
DT Utility  
FS APPLICATION  
LN.CNT 567  
INCL INCLM: 424/497.000  
INCLS: 424/490.000; 514/603.000  
NCL NCLM: 424/497.000  
NCLS: 424/490.000; 514/603.000  
IC IPCI A61K0009-14 [I,A]; A61K0031-18 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 2 USPATFULL on STN

Full Text

AN 2008:253184 USPATFULL  
TI Advanced drug development and manufacturing  
IN Birnbaum, Eva R., Los Alamos, NM, UNITED STATES  
Koppisch, Andrew T., Flagstaff, AZ, UNITED STATES  
Baldwin, Sharon M., Santa Fe, NM, UNITED STATES  
Warner, Benjamin P., Los Alamos, NM, UNITED STATES  
McCleskey, T. Mark, Los Alamos, NM, UNITED STATES  
Stewart, Jeffrey Joseph, Los Alamos, NM, UNITED STATES  
Berger, Jennifer A., Los Alamos, NM, UNITED STATES  
Harris, Michael N., Los Alamos, NM, UNITED STATES  
Burrell, Anthony K., Los Alamos, NM, UNITED STATES  
PI US 20080220441 A1 20080911  
AI US 2007-974156 A1 20071010 (11)  
RLI Continuation-in-part of Ser. No. US 2001-859701, filed on 16 May 2001,  
PENDING Continuation-in-part of Ser. No. US 2002-206524, filed on 25 Jul  
2002, ABANDONED Continuation-in-part of Ser. No. US 2003-621825, filed  
on 16 Jul 2003, Pat. No. US 6858148  
PRAI US 2006-850594P 20061010 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 10199  
INCL INCLM: 435/071.000  
INCLS: 436/501.000; 436/172.000; 436/086.000; 378/045.000  
NCL NCLM: 435/007.100  
NCLS: 378/045.000; 436/086.000; 436/172.000; 436/501.000  
IC IPCI G01N0033-53 [I,A]; G01N0021-76 [I,A]; G01N0033-68 [I,A];  
G01N0023-223 [I,A]; G01N0023-22 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

-> d 118 1-6

L18 ANSWER 1 OF 6 USPATFULL on STN

Full Text

AN 2009:4272 USPATFULL  
TI Controlled release tamsulosin hydrochloride formulation  
IN Cheng, Xiu Xiu, Weston, FL, UNITED STATES  
Cheng, Xiufang, Weston, FL, UNITED STATES  
PA Watson Pharmaceuticals, Inc. (U.S. corporation)  
PI US 20090004284 A1 20090101  
AI US 2007-821990 A1 20070626 (11)  
DT Utility  
FS APPLICATION  
LN.CNT 567  
INCL INCLM: 424/497.000  
INCLS: 424/490.000; 514/603.000  
NCL NCLM: 424/497.000  
NCLS: 424/490.000; 514/603.000  
IC IPCI A61K0009-14 [I,A]; A61K0031-18 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 6 USPATFULL on STN

Full Text

AN 2008:354338 USPATFULL  
TI Solid form  
IN Darmuzey, Olivia, Brussels, BELGIUM  
MacLeod, Graeme, Wezembeek Oppem, BELGIUM  
Cengic, Dzenana, Brussels, BELGIUM  
PI US 20080311162 A1 20081218  
AI US 2007-803825 A1 20070516 (11)  
DT Utility  
FS APPLICATION  
LN.CNT 1512  
INCL INCLM: 424/401.000  
INCLS: 424/490.000; 514/263.340  
NCL NCLM: 424/401.000  
NCLS: 424/490.000; 514/263.340  
IC IPCI A61K0008-02 [I,A]; A61K0009-14 [I,A]; A61K0031-522 [I,A];  
A61K0031-519 [I,C\*]; C11D0017-06 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 6 USPATFULL on STN

Full Text

AN 2008:268489 USPATFULL  
TI UROLOGICAL MEDICAL DEVICES FOR RELEASE OF THERAPEUTIC AGENTS  
IN Cheng, Eric, Bloomington, IN, UNITED STATES  
Li, Jianmin, Lexington, MA, UNITED STATES  
Bucay-Couto, Weena, Burlington, MA, UNITED STATES  
Sanders, Scott, Hinsdale, IL, UNITED STATES  
Schuermann, James F., Natick, MA, UNITED STATES  
Sheu, Min-Shyan, Chelmsford, MA, UNITED STATES  
PA Boston Scientific Scimed, Inc., Maple Grove, MN, UNITED STATES (U.S.  
corporation)  
PI US 20080234659 A1 20080925  
AI US 2008-52037 A1 20080320 (12)  
PRAI US 2007-919081P 20070320 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1180  
INCL INCLM: 604/523.000  
INCLS: 623/023.660  
NCL NCLM: 604/523.000  
NCLS: 623/023.660  
IC IPCI A61M0025-00 [I,A]; A61F0002-04 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 6 USPATFULL on STN

Full Text

AN 2008:253184 USPATFULL  
TI Advanced drug development and manufacturing  
IN Birnbaum, Eva R., Los Alamos, NM, UNITED STATES  
Koppisch, Andrew T., Flagstaff, AZ, UNITED STATES  
Baldwin, Sharon M., Santa Fe, NM, UNITED STATES  
Warner, Benjamin P., Los Alamos, NM, UNITED STATES  
McCleskey, T. Mark, Los Alamos, NM, UNITED STATES  
Stewart, Jeffrey Joseph, Los Alamos, NM, UNITED STATES  
Berger, Jennifer A., Los Alamos, NM, UNITED STATES  
Harris, Michael N., Los Alamos, NM, UNITED STATES  
Burrell, Anthony K., Los Alamos, NM, UNITED STATES  
PI US 20080220441 A1 20080911  
AI US 2007-974156 A1 20071010 (11)  
RLI Continuation-in-part of Ser. No. US 2001-859701, filed on 16 May 2001,  
PENDING Continuation-in-part of Ser. No. US 2002-206524, filed on 25 Jul  
2002, ABANDONED Continuation-in-part of Ser. No. US 2003-621825, filed  
on 16 Jul 2003, Pat. No. US 6858148  
PRAI US 2006-850594P 20061010 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 10199  
INCL INCLM: 435/071.000  
INCLS: 436/501.000; 436/172.000; 436/086.000; 378/045.000  
NCL NCLM: 435/007.100  
NCLS: 378/045.000; 436/086.000; 436/172.000; 436/501.000

IC IPCI G01N0033-53 [I,A]; G01N0021-76 [I,A]; G01N0033-68 [I,A];  
G01N0023-223 [I,A]; G01N0023-22 [I,C\*]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 6 USPATFULL on STN

Full Text

AN 2008:86578 USPATFULL  
TI Tamsulosin controlled-release tablet  
IN Gan, Yong, Huairou, CHINA  
Zhou, Xinteng, Huairou, CHINA  
PA Ocean Star International, Inc., Snowville, UT, UNITED STATES (non-U.S.  
corporation)  
PI US 20080075775 A1 20080327  
AI US 2006-580215 A1 20061011 (11)  
PRAI CN 2006-10153091 20060922  
DT Utility  
FS APPLICATION  
LN.CNT 720  
INCL INCLM: 424/473.000  
NCL NCLM: 424/473.000  
IC IPCI A61K0009-24 [I,A]  
IPCR A61K0009-24 [I,C]; A61K0009-24 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 6 USPATFULL on STN

Full Text

AN 2007:140489 USPATFULL  
TI Sustained release formulations  
IN Cho, Seong Hwan, Suwon-city, KOREA, REPUBLIC OF  
Ku, Jeong, Yongin-city, KOREA, REPUBLIC OF  
Lim, Dong Kwon, Yongin-city, KOREA, REPUBLIC OF  
Cheon, Jun Hee, Suwon-city, KOREA, REPUBLIC OF  
An, Tae Kun, Yongin-city, KOREA, REPUBLIC OF  
Ko, Jae Kyoung, Incheon-city, KOREA, REPUBLIC OF  
Youn, Yong Sik, Yongin-city, KOREA, REPUBLIC OF  
Park, Choong Sil, Icheon-city, KOREA, REPUBLIC OF  
Suh, Hea Ran, Icheon-city, KOREA, REPUBLIC OF  
Yang, Eun Young, Suwon-city, KOREA, REPUBLIC OF  
Jeon, Eun Kyung, Yongin-city, KOREA, REPUBLIC OF  
Kim, Chang Ju, Suwon-city, KOREA, REPUBLIC OF  
PA CJ CORPORATION, Seoul, KOREA, REPUBLIC OF, 100-749 (non-U.S.  
corporation)  
PI US 20070122480 A1 20070531  
AI US 2004-574337 A1 20040925 (10)  
WO 2004-KR2496 20040925  
20060509 PCT 371 date  
PRAI KR 2003-67588 20030929  
KR 2004-77158 20040924  
DT Utility  
FS APPLICATION  
LN.CNT 799  
INCL INCLM: 424/472.000  
NCL NCLM: 424/472.000  
IC IPCI A61K0009-24 [I,A]  
IPCR A61K0009-24 [I,C]; A61K0009-24 [I,A]; A61K0009-22 [I,C\*];  
A61K0009-22 [I,A]  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

-> d his

(FILE 'HOME' ENTERED AT 22:22:24 ON 13 MAR 2009)

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 22:26:23 ON 13 MAR 2009

L1 1288 S TAMSULOSIN  
L2 226 S TAMSULOSIN/CLM  
L3 1224605 S POLYMER?  
L4 432182 S POLYMER?/CLM  
L5 1287207 S (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)  
L6 305082 S (CALCIUM OR POTASSIUM OR SODIUM OR MAGNESIUM)/CLM  
L7 2063906 S (MULTILAYER OR LAYER)  
L8 810896 S (MULTILAYER OR LAYER)/CLM

L9 243183 S CAPSULE?  
 L10 27197 S CAPSULE?/CLM  
 L11 242 S L1 AND L4  
 L12 897 S L1 AND L3  
 L13 888 S L5 AND L12  
 L14 600 S L7 AND L13  
 L15 493 S L9 AND L14  
 L16 50 S L2 AND L4  
 L17 33 S L6 AND L16  
 L18 6 S L8 AND L17  
 L19 2 S L10 AND L18

=> d l15 483-493

L15 ANSWER 483 OF 493 USPAT2 on SIN

Full Text

AN 2003:100119 USPAT2  
 TI Quinazalone derivatives as alpha 1A/B adrenergic receptor antagonists  
 IN Becker, Cyrus Kephra, Menlo Park, CA, UNITED STATES  
 Caroon, Joan Marie, Mountain View, CA, UNITED STATES  
 Melville, Chris Richard, Palo Alto, CA, UNITED STATES  
 Padilla, Fernando, Fremont, CA, UNITED STATES  
 Pfister, Jurg Roland, Los Altos, CA, UNITED STATES  
 Zhang, Xiaoming, Campbell, CA, UNITED STATES  
 PA Syntex (U.S.A.) LLC, Palo Alto, CA, UNITED STATES (U.S. corporation)  
 PI US 6900220 B2 20050531  
 AI US 2002-40319 20020102 (10)  
 PRAI US 2001-259337P 20010102 (60)  
 US 2001-325267P 20010927 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2798  
 INCL INCLM: 514/266.210  
 INCLS: 514/234.200; 514/234.500; 514/249.000; 514/252.170; 514/264.100;  
 514/266.200; 544/116.000; 544/117.000; 544/279.000; 544/284.000;  
 544/350.000  
 NCL NCLM: 514/266.210; 514/223.200  
 NCLS: 514/234.200; 514/234.500; 514/249.000; 514/252.170; 514/264.100;  
 514/266.200; 544/116.000; 544/117.000; 544/279.000; 544/284.000;  
 544/350.000; 544/012.000  
 IC [7]  
 ICM A61K031-517  
 ICS A61K031-535; C07D487-00; C07D417-00; C07D471-00  
 IPCI C07D0285-22 [ICM,7]; C07D0285-00 [ICM,7,C\*]; A61K0031-549  
 [ICS,7]; A61K0031-517 [ICS,7]  
 IPCI-2 A61K0031-517 [ICM,7]; A61K0031-535 [ICS,7]; C07D0487-00 [ICS,7];  
 C07D0417-00 [ICS,7]; C07D0471-00 [ICS,7]  
 IPCR A61K0031-517 [I,C\*]; A61K0031-517 [I,A]; A61K0031-519 [I,C\*];  
 A61K0031-519 [I,A]; A61K0031-549 [I,C\*]; A61K0031-549 [I,A];  
 C07D0401-00 [I,C\*]; C07D0401-04 [I,A]; C07D0401-14 [I,A];  
 C07D0403-00 [I,C\*]; C07D0403-14 [I,A]; C07D0405-00 [I,C\*];  
 C07D0405-14 [I,A]; C07D0417-00 [I,C\*]; C07D0417-04 [I,A];  
 C07D0417-14 [I,A]; C07D0471-00 [I,C\*]; C07D0471-04 [I,A];  
 C07D0471-14 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A];  
 C07D0491-00 [I,C\*]; C07D0491-04 [I,A]  
 EXF 514/234.2; 514/234.5; 514/249; 514/252.17; 514/264.1; 514/266.2;  
 514/266.21; 544/116; 544/117; 544/279; 544/284; 544/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 484 OF 493 USPAT2 on SIN

Full Text

AN 2003:92739 USPAT2  
 TI Solid carriers for improved delivery of hydrophobic active ingredients  
 in pharmaceutical compositions  
 IN Patel, Mahesh V., Salt Lake City, UT, United States  
 Chen, Feng-Jing, Salt Lake City, UT, United States  
 PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)  
 PI US 6569463 B2 20030527  
 AI US 2001-800593 20010306 (9)  
 RLI Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, now patented,  
 Pat. No. US 6248363  
 DT Utility

FS GRANTED  
LN.CNT 3198  
INCL INCLM: 424/497.000  
INCLS: 424/422.000; 424/427.000; 424/430.000; 424/433.000; 424/434.000;  
424/435.000; 424/436.000; 424/441.000; 424/451.000; 424/457.000;  
424/463.000; 424/464.000; 424/465.000; 424/466.000; 424/470.000;  
424/474.000; 424/476.000; 424/482.000; 424/490.000; 424/489.000;  
424/498.000; 514/773.000; 514/784.000; 514/785.000; 514/786.000;  
514/779.000  
NCL NCLM: 424/497.000; 424/465.000  
NCLS: 424/422.000; 424/427.000; 424/430.000; 424/433.000; 424/434.000;  
424/435.000; 424/436.000; 424/441.000; 424/451.000; 424/457.000;  
424/463.000; 424/464.000; 424/465.000; 424/466.000; 424/470.000;  
424/474.000; 424/476.000; 424/482.000; 424/489.000; 424/490.000;  
424/498.000; 514/773.000; 514/779.000; 514/784.000; 514/785.000;  
514/786.000; 977/906.000; 977/927.000  
IC [7]  
ICM A61K009-16  
ICS A61K009-28; A61K009-32; A61K009-52; A61K009-56; A61K009-58  
IPCI A61K0009-20 [ICM,7]; A61K0009-16 [ICS,7]; A61K0009-50 [ICS,7]  
IPCI-2 A61K0009-16 [ICM,7]; A61K0009-28 [ICS,7]; A61K0009-32 [ICS,7];  
A61K0009-30 [ICS,7,C\*]; A61K0009-52 [ICS,7]; A61K0009-56 [ICS,7];  
IPCR A61K0009-58 [ICS,7]; A61K0009-52 [ICS,7,C\*]  
A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-14 [I,C\*];  
A61K0009-14 [I,A]; A61K0009-16 [I,C\*]; A61K0009-16 [I,A];  
A61K0009-20 [I,C\*]; A61K0009-20 [I,A]; A61K0009-30 [I,C\*];  
A61K0009-32 [I,A]; A61K0009-48 [I,C\*]; A61K0009-48 [I,A];  
A61K0009-50 [I,C\*]; A61K0009-50 [I,A]; A61K0009-51 [I,C\*];  
A61K0009-51 [I,A]; A61K0009-52 [I,C\*]; A61K0009-52 [I,A];  
A61K0009-54 [I,A]; A61K0009-56 [I,A]; A61K0009-58 [I,A];  
A61K0031-21 [I,C\*]; A61K0031-216 [I,A]; A61K0031-232 [I,A];  
A61K0031-351 [I,C\*]; A61K0031-351 [I,A]; A61K0031-366 [I,C\*];  
A61K0031-366 [I,A]; A61K0031-40 [I,C\*]; A61K0031-40 [I,A];  
A61K0031-403 [I,C\*]; A61K0031-404 [I,A]; A61K0031-415 [I,C\*];  
A61K0031-415 [I,A]; A61K0031-4196 [I,C\*]; A61K0031-4196 [I,A];  
A61K0031-421 [I,C\*]; A61K0031-421 [I,A]; A61K0031-4353 [I,C\*];  
A61K0031-436 [I,A]; A61K0031-4409 [I,C\*]; A61K0031-4409 [I,A];  
A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-472 [I,C\*];  
A61K0031-4725 [I,A]; A61K0031-519 [I,C\*]; A61K0031-522 [I,A];  
A61K0031-57 [I,C\*]; A61K0031-57 [I,A]; A61K0031-64 [I,C\*];  
A61K0031-64 [I,A]; A61K0031-662 [I,C\*]; A61K0031-663 [I,A];  
A61K0038-23 [I,C\*]; A61K0038-23 [I,A]; A61K0047-02 [I,C\*];  
A61K0047-02 [I,A]; A61K0047-10 [I,C\*]; A61K0047-10 [I,A];  
A61K0047-14 [I,C\*]; A61K0047-14 [I,A]; A61K0047-22 [I,C\*];  
A61K0047-22 [I,A]; A61K0047-26 [I,C\*]; A61K0047-26 [I,A];  
A61K0047-28 [I,C\*]; A61K0047-28 [I,A]; A61K0047-32 [I,C\*];  
A61K0047-32 [I,A]; A61K0047-36 [I,C\*]; A61K0047-36 [I,A];  
A61K0047-38 [I,C\*]; A61K0047-38 [I,A]; A61K0047-44 [I,C\*];  
A61K0047-44 [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A];  
A61P0003-00 [I,C\*]; A61P0003-04 [I,A]; A61P0003-06 [I,A];  
A61P0003-10 [I,A]; A61P0005-00 [I,C\*]; A61P0005-16 [I,A];  
A61P0005-24 [I,A]; A61P0005-40 [I,A]; A61P0007-00 [I,C\*];  
A61P0007-02 [I,A]; A61P0007-10 [I,A]; A61P0009-00 [I,C\*];  
A61P0009-04 [I,A]; A61P0009-06 [I,A]; A61P0009-10 [I,A];  
A61P0009-12 [I,A]; A61P0013-00 [I,C\*]; A61P0013-08 [I,A];  
A61P0015-00 [I,C\*]; A61P0015-10 [I,A]; A61P0017-00 [I,C\*];  
A61P0017-12 [I,A]; A61P0019-00 [I,C\*]; A61P0019-06 [I,A];  
A61P0019-10 [I,A]; A61P0021-00 [I,C\*]; A61P0021-02 [I,A];  
A61P0025-00 [I,C\*]; A61P0025-04 [I,A]; A61P0025-06 [I,A];  
A61P0025-08 [I,A]; A61P0025-16 [I,A]; A61P0025-20 [I,A];  
A61P0025-22 [I,A]; A61P0025-26 [I,A]; A61P0025-28 [I,A];  
A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0031-00 [I,C\*];  
A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];  
A61P0033-00 [I,C\*]; A61P0033-06 [I,A]; A61P0033-10 [I,A];  
A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0037-00 [I,C\*];  
A61P0037-06 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]  
EXF 424/422; 424/433; 424/436; 424/435; 424/440; 424/451; 424/452; 424/464;  
424/465; 424/482; 424/489; 424/490; 424/480; 424/463; 424/470; 424/497;  
424/498; 424/476; 424/427; 424/430; 424/434; 424/441; 424/466; 424/474  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Full Text

AN 2003:78121 USPAT2  
TI Modified release formulations containing a hypnotic agent  
IN Lemmens, Jacobus M., Mook, NETHERLANDS  
van den Heuvel, Dennie J. M., Boxmeer, NETHERLANDS  
Platteeuw, Johannes J., s'Hertogenbosch, NETHERLANDS  
van Dalen, Frans, Nijmegen, NETHERLANDS  
PA Synthon BV, Nijmegen, NETHERLANDS (non-U.S. corporation)  
PI US 6638535 B2 20031028  
AI US 2001-833662 20010413 (9)  
PRAI US 2000-196939P 20000413 (60)  
DT Utility  
FS GRANTED  
LN.CNT 902  
INCL INCLM: 424/489.000  
INCLS: 424/490.000; 424/464.000; 424/465.000; 514/300.000; 514/781.000  
NCL NCLM: 424/489.000  
NCLS: 424/464.000; 424/465.000; 424/490.000; 514/300.000; 514/781.000  
IC [7]  
ICM A61K009-20  
ICS A61K009-14; A61K009-16; A61K031-44; A61K047-00  
IPCI A61K009-14 [ICM,7]  
IPCI-2 A61K009-20 [ICM,7]; A61K009-14 [ICS,7]; A61K009-16 [ICS,7];  
A61K0031-44 [ICS,7]; A61K047-00 [ICS,7]  
IPCR A61K009-16 [I,C\*]; A61K009-16 [I,A]; A61K009-26 [I,C\*];  
A61K009-26 [I,A]; A61K0031-4353 [I,C\*]; A61K0031-437 [I,A];  
A61K0031-519 [I,C\*]; A61K0031-519 [I,A]  
EXF 424/489; 424/490; 424/464; 424/465; 514/300; 514/781  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 486 OF 493 USPAT2 on SIN

Full Text

AN 2002:308400 USPAT2  
TI Heterocyclic compounds their production and use  
IN Tasaka, Akihiro, Suita, JAPAN  
Hitaka, Takenori, Takarazuka, JAPAN  
Matsutani, Etsuya, Suita, JAPAN  
PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)  
PI US 6716863 B2 20040406  
WO 2001077107 20011018  
AI US 2001-889974 20010724 (9)  
WO 2001-JP2937 20010405  
PRAI JP 2000-106836 20000407  
DT Utility  
FS GRANTED  
LN.CNT 3144  
INCL INCLM: 514/374.000  
INCLS: 548/235.000  
NCL NCLM: 514/374.000  
NCLS: 548/235.000  
IC [7]  
ICM A61K031-422  
ICS C07D413-12  
IPCI C07D0413-02 [ICM,7]; C07D0413-00 [ICM,7,C\*]; A61K0031-422 [ICS,7]  
IPCI-2 A61K0031-422 [ICM,7]; C07D0413-12 [ICS,7]; C07D0413-00 [ICS,7,C\*]  
IPCR A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; C07D0263-00 [I,C\*];  
C07D0263-32 [I,A]; C07D0413-00 [I,C\*]; C07D0413-12 [I,A]  
EXF 514/374; 548/235  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 487 OF 493 USPAT2 on SIN

Full Text

AN 2002:301622 USPAT2  
TI Benzimidazoles that are useful in treating male sexual dysfunction  
IN Cowart, Marlon D., Round Lake Beach, IL, UNITED STATES  
Bhatia, Pramila A., Libertyville, IL, UNITED STATES  
Daanen, Jerome F., Racine, WI, UNITED STATES  
Stewart, Andrew O., Libertyville, IL, UNITED STATES  
Patel, Meena V., Green Oaks, IL, UNITED STATES  
Kolasa, Teodozyj, Lake Villa, IL, UNITED STATES  
Brioni, Jorge D., Vernon Hills, IL, UNITED STATES  
Rohde, Jeffrey, Evanston, IL, UNITED STATES

PA Abbott Laboratories, Abbott Park, IL, UNITED STATES (U.S. corporation)  
 PI US 7022728 B2 20060404  
 AI US 2002-94265 20020308 (10)  
 PRAI US 2001-340452P 20011214 (60)  
 US 2001-296078P 20010605 (60)  
 US 2001-274805P 20010309 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 2990  
 INCL INCLM: 514/395.000  
 INCLS: 514/394.000; 514/393.000; 514/252.140; 514/254.060; 514/253.010  
 NCL NCLM: 514/395.000; 514/252.190  
 NCLS: 514/252.140; 514/253.010; 514/254.060; 514/393.000; 514/394.000;  
 514/253.090; 514/254.030  
 IC IPCI A61K0031-496 [ICM,7]  
 IPCI-2 A61K0031-415 [I,A]; A61K0031-495 [I,A]; A61K0031-50 [I,A]  
 IPCR A61K0031-496 [I,C\*]; A61K0031-496 [I,A]; A61K0031-415 [I,A];  
 A61K0031-415 [I,C]; A61K0031-495 [I,C]; A61K0031-495 [I,A];  
 A61K0031-50 [I,C]; A61K0031-50 [I,A]  
 EXF 514/255; 514/258; 514/394; 514/393; 514/359; 514/362; 514/363; 514/385;  
 514/395; 514/252.14; 514/254.06; 514/253.01  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 488 OF 493 USPAT2 on SIN

Full Text

AN 2002:288146 USPAT2  
 TI As-needed administration of tricyclic and other non-SRI antidepressant  
 drugs to treat premature ejaculation  
 IN Tam, Peter, Redwood City, CA, UNITED STATES  
 Gesundheit, Neil, Los Altos, CA, UNITED STATES  
 Wilson, Leland F., Menlo Park, CA, UNITED STATES  
 PA Vivus, Inc., Mountain View, CA, UNITED STATES (U.S. corporation)  
 PI US 6946141 B2 20050920  
 AI US 2001-996407 20011121 (9)  
 RLI Continuation-in-part of Ser. No. US 2000-721412, filed on 21 Nov 2000,  
 Pat. No. US 6495154  
 DT Utility  
 FS GRANTED  
 LN.CNT 1495  
 INCL INCLM: 424/423.000  
 INCLS: 424/434.000; 424/435.000; 424/443.000; 424/449.000; 424/451.000;  
 424/464.000; 424/045.000; 424/046.000  
 NCL NCLM: 424/423.000; 514/278.000  
 NCLS: 424/045.000; 424/046.000; 424/434.000; 424/435.000; 424/443.000;  
 424/449.000; 424/451.000; 424/464.000  
 IC [7]  
 ICM A61F002-02  
 ICS A61F013-02; A61K009-48; A61K009-70; A61K009-04  
 IPCI A61K0031-44 [ICM,7]  
 IPCI-2 A61F0002-02 [ICM,7]; A61F0013-02 [ICS,7]; A61K0009-48 [ICS,7];  
 A61K0009-70 [ICS,7]; A61K0009-04 [ICS,7]  
 IPCR A61K0009-02 [I,C\*]; A61K0009-02 [I,A]; A61K0009-08 [I,C\*];  
 A61K0009-08 [I,A]; A61K0009-12 [I,C\*]; A61K0009-12 [I,A];  
 A61K0009-19 [I,C\*]; A61K0009-19 [I,A]; A61K0009-20 [I,C\*];  
 A61K0009-20 [I,A]; A61K0009-46 [I,C\*]; A61K0009-46 [I,A];  
 A61K0031-135 [I,C\*]; A61K0031-135 [I,A]; A61K0031-136 [I,C\*];  
 A61K0031-136 [I,A]; A61K0031-403 [I,C\*]; A61K0031-404 [I,A];  
 A61K0031-55 [I,C\*]; A61K0031-55 [I,A]; A61K0031-551 [I,C\*];  
 A61K0031-551 [I,A]; A61K0031-553 [I,C\*]; A61K0031-553 [I,A];  
 A61K0031-554 [I,C\*]; A61K0031-554 [I,A]; A61K0045-00 [I,C\*];  
 A61K0045-00 [I,A]; A61K0045-06 [I,A]; A61K0047-34 [I,C\*];  
 A61K0047-34 [I,A]; A61P0015-00 [I,C\*]; A61P0015-00 [I,A];  
 A61P0043-00 [I,C\*]; A61P0043-00 [I,A]  
 EXF 424/423; 424/434; 424/435; 424/443; 424/449; 424/451; 424/464; 424/45;  
 424/46  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 489 OF 493 USPAT2 on SIN

Full Text

AN 2002:67175 USPAT2  
 TI Administration of phosphodiesterase inhibitors for the treatment of  
 premature ejaculation

IN Wilson, Leland F., Menlo Park, CA, United States  
Doherty, Jr., Paul C., Cupertino, CA, United States  
Place, Virgil A., Kawaihae, HI, United States  
Smith, William L., Montclair, NJ, United States  
Abdel-Hamid Abdou Ali, Ibrahim AbouBakr, Mansoura, EGYPT  
PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)  
PI US 6403597 B2 20020611  
AI US 2001-888250 20010621 (9)  
RLI Continuation-in-part of Ser. No. US 1999-467094, filed on 10 Dec 1999  
Continuation-in-part of Ser. No. US 1998-181070, filed on 27 Oct 1998,  
now patented, Pat. No. US 6037346, issued on 14 Mar 2000  
Continuation-in-part of Ser. No. US 1997-958816, filed on 28 Oct 1997,  
now abandoned  
DT Utility  
FS GRANTED  
LN.CNT 2030  
INCL INCLM: 514/256.000  
NCL NCLM: 514/256.000; 514/001.000  
IC [7]  
ICM A61K031-50  
IPCI A61K0031-00 [I,C\*,7]  
IPCI-2 A61K0031-50 [I,C\*,7]  
IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0031-00 [I,C\*];  
A61K0031-00 [I,A]; A61K0031-343 [I,C\*]; A61K0031-343 [I,A];  
A61K0031-381 [I,C\*]; A61K0031-381 [I,A]; A61K0031-40 [I,C\*];  
A61K0031-40 [I,A]; A61K0031-4015 [I,C\*]; A61K0031-4015 [I,A];  
A61K0031-4164 [I,C\*]; A61K0031-4164 [I,A]; A61K0031-4166 [I,A];  
A61K0031-426 [I,C\*]; A61K0031-426 [I,A]; A61K0031-4353 [I,C\*];  
A61K0031-437 [I,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A];  
A61K0031-444 [I,A]; A61K0031-4704 [I,C\*]; A61K0031-4704 [I,A];  
A61K0031-4709 [I,C\*]; A61K0031-4709 [I,A]; A61K0031-4738 [I,C\*];  
A61K0031-4745 [I,A]; A61K0031-496 [I,C\*]; A61K0031-496 [I,A];  
A61K0031-50 [I,C\*]; A61K0031-50 [I,A]; A61K0031-502 [I,C\*];  
A61K0031-502 [I,A]; A61K0031-5025 [I,C\*]; A61K0031-5025 [I,A];  
A61K0031-505 [I,C\*]; A61K0031-505 [I,A]; A61K0031-519 [I,C\*];  
A61K0031-519 [I,A]; A61K0031-52 [I,A]; A61K0031-522 [I,A];  
A61K0031-5375 [I,C\*]; A61K0031-538 [I,A]; A61K0031-549 [I,C\*];  
A61K0031-549 [I,A]; A61K0031-551 [I,C\*]; A61K0031-5513 [I,A];  
A61K0045-00 [I,C\*]; A61K0045-06 [I,A]  
EXF 514/258  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L15 ANSWER 490 OF 493 USPAT2 on SIN  
Full Text  
AN 2002:55008 USPAT2  
TI Clear oil-containing pharmaceutical compositions containing a  
therapeutic agent  
IN Chen, Feng-Jing, Salt Lake City, UT, United States  
Patel, Mahesh V., Salt Lake City, UT, United States  
Fikstad, David T., Salt Lake City, UT, United States  
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)  
PI US 6761903 B2 20040713  
AI US 2001-877541 20010608 (9)  
RLI Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999,  
now patented, Pat. No. US 6267985 Continuation-in-part of Ser. No. US  
2000-751968, filed on 29 Dec 2000, now patented, Pat. No. US 6458383  
Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999,  
now patented, Pat. No. US 6309663  
DT Utility  
FS GRANTED  
LN.CNT 3614  
INCL INCLM: 424/451.000  
INCLS: 424/043.000; 424/433.000; 424/436.000; 424/441.000; 424/445.000;  
424/455.000; 424/456.000; 424/458.000; 424/463.000; 424/464.000;  
424/465.000; 424/489.000; 424/490.000; 424/725.000; 514/772.200;  
514/772.300; 514/777.000; 514/779.000; 514/781.000; 514/783.000;  
514/784.000; 514/785.000; 514/786.000; 514/937.000; 514/944.000  
NCL NCLM: 424/451.000; 514/054.000  
NCLS: 424/043.000; 424/433.000; 424/436.000; 424/441.000; 424/445.000;  
424/455.000; 424/456.000; 424/458.000; 424/463.000; 424/464.000;  
424/465.000; 424/489.000; 424/490.000; 424/725.000; 514/772.200;  
514/772.300; 514/777.000; 514/779.000; 514/781.000; 514/783.000;

514/784.000; 514/785.000; 514/786.000; 514/937.000; 514/944.000;  
 424/727.000; 424/731.000; 424/750.000; 424/757.000

IC [7]  
 ICM A61K009-08  
 ICS A61K009-10; A61K009-14; A61K009-20; A61K009-48  
 IPCI A61K0031-715 [ICM,7]; A61K0035-78 [ICS,7]  
 IPCI-2 A61K0009-08 [ICM,7]; A61K0009-10 [ICS,7]; A61K0009-14 [ICS,7];  
 A61K0009-20 [ICS,7]; A61K0009-48 [ICS,7]  
 IPCR A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0036-185 [I,C\*];  
 A61K0036-47 [I,A]

EXF 424/451; 424/450; 424/433; 424/436; 424/441; 424/443; 424/445  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 491 OF 493 USPAT2 on SIN

Full Text

AN 2002:27516 USPAT2  
 TI Compounds and methods to increase plasma HDL cholesterol levels and  
 improve HDL functionality  
 IN Luchoomun, Jayraz, Lilburn, GA, UNITED STATES  
 Meng, Charles O., Alpharetta, GA, UNITED STATES  
 Saxena, Uday, Atlanta, GA, UNITED STATES  
 Sikorski, James A., Alpharetta, GA, UNITED STATES  
 PA Atherogenics, Inc., Alpharetta, GA, UNITED STATES (U.S. corporation)  
 PI US 6881860 B2 20050419  
 AI US 2001-833407 20010411 (9)  
 PRAI US 2000-196201P 20000411 (60)  
 DT Utility  
 FS GRANTED  
 LN.CNT 3107  
 INCL INCLM: 562/426.000  
 INCLS: 514/568.000  
 NCL NCLM: 562/426.000; 514/517.000  
 NCLS: 514/571.000; 514/649.000; 558/037.000; 564/347.000  
 IC [7]  
 ICM C07C321-00  
 IPCI A61K0031-255 [ICM,7]; A61K0031-21 [ICM,7,C\*]; A61K0031-192  
 [ICS,7]; A61K0031-185 [ICS,7,C\*]; A61K0031-145 [ICS,7]  
 IPCI-2 C07C0321-00 [ICM,7]  
 IPCR C07C0323-00 [I,C\*]; C07C0323-20 [I,A]; G01N0033-92 [I,C\*];  
 G01N0033-92 [I,A]

EXF 562/426; 514/568  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 492 OF 493 USPAT2 on SIN

Full Text

AN 2002:21845 USPAT2  
 TI Compositions and methods for improved delivery of hydrophobic agents  
 IN Patel, Mahesh V., Salt Lake City, UT, United States  
 Chen, Feng-Jing, Salt Lake City, UT, United States  
 PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)  
 PI US 6451339 B2 20020917  
 AI US 2001-898553 20010702 (9)  
 RLI Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, now  
 patented, Pat. No. US 6294192  
 DT Utility  
 FS GRANTED  
 LN.CNT 2907  
 INCL INCLM: 424/451.000  
 INCLS: 424/450.000; 424/455.000; 424/456.000; 424/463.000; 424/489.000;  
 424/499.000; 424/502.000; 424/435.000; 424/464.000; 424/937.000;  
 424/938.000; 424/939.000; 514/940.000; 514/941.000; 514/942.000;  
 514/943.000; 514/975.000  
 NCL NCLM: 424/451.000; 424/400.000  
 NCLS: 424/435.000; 424/450.000; 424/455.000; 424/456.000; 424/463.000;  
 424/464.000; 424/489.000; 424/499.000; 424/502.000; 514/937.000;  
 514/938.000; 514/939.000; 514/940.000; 514/941.000; 514/942.000;  
 514/943.000; 514/975.000

IC [7]  
 ICM A61K009-127  
 IPCI A61K0009-00 [ICM,7]  
 IPCI-2 A61K0009-127 [ICM,7]  
 IPCR A61K0009-48 [I,C\*]; A61K0009-48 [I,A]; A61K0031-57 [I,C\*];

A61K0031-57 [I,A]; A61K0038-12 [I,C\*]; A61K0038-13 [I,A]  
 EXF 424/450; 424/451; 424/455; 424/456; 424/463; 424/489; 424/499; 424/502;  
 424/435; 424/464; 514/937; 514/938; 514/939; 514/940; 514/941; 514/943;  
 514/975  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 493 OF 493 USPAT2 on SIN

Full Text

AN 2001:229703 USPAT2  
 TI Co-administration of a prostaglandin and an androgenic agent in the  
 treatment of female sexual dysfunction  
 IN Place, Virgil A., Kawaihae, HI, United States  
 Wilson, Leland F., Menlo Park, CA, United States  
 Doherty, Jr., Paul C., Cupertino, CA, United States  
 Hanamoto, Mark S., Belmont, CA, United States  
 Spivack, Alfred P., Menlo Park, CA, United States  
 Gesundheit, Neil, Los Altos, CA, United States  
 Bennett, Sean R., Denver, CO, United States  
 PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)  
 PI US 6593313 B2 20030715  
 AI US 2001-905458 20010713 (9)  
 RLI Continuation of Ser. No. US 2000-539484, filed on 30 Mar 2000, now  
 patented, Pat. No. US 6306841 Continuation of Ser. No. US 1998-181316,  
 filed on 27 Oct 1998, now abandoned Continuation-in-part of Ser. No. US  
 1997-959064, filed on 28 Oct 1997, now patented, Pat. No. US 5877216  
 Continuation-in-part of Ser. No. US 1997-959057, filed on 28 Oct 1997,  
 now abandoned  
 DT Utility  
 FS GRANTED  
 LN.CNT 1331  
 INCL INCLM: 514/108.000  
 NCL NCLM: 514/108.000; 514/530.000  
 NCLS: 514/288.000; 514/573.000  
 IC [7]  
 ICM A61K031-19  
 ICS A61K031-557  
 IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C\*]; A61K0031-48  
 [ICS,7]  
 IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C\*]; A61K0031-557  
 [ICS,7]  
 IPCR A61K0009-00 [I,C\*]; A61K0009-00 [I,A]; A61K0009-02 [N,C\*];  
 A61K0009-02 [N,A]; A61K0031-00 [I,C\*]; A61K0031-00 [I,A];  
 A61K0031-15 [I,C\*]; A61K0031-15 [I,A]; A61K0031-21 [I,C\*];  
 A61K0031-21 [I,A]; A61K0031-28 [I,C\*]; A61K0031-295 [I,A];  
 A61K0031-48 [I,C\*]; A61K0031-48 [I,A]; A61K0031-5375 [I,C\*];  
 A61K0031-5377 [I,A]; A61K0031-557 [I,C\*]; A61K0031-557 [I,A];  
 A61K0031-5575 [I,A]; A61K0031-5585 [I,A]; A61K0031-56 [I,C\*];  
 A61K0031-56 [I,A]; A61K0045-00 [I,C\*]; A61K0045-06 [I,A]  
 EXF 514/573  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

-> d l15 kwic 492

L15 ANSWER 492 OF 493 USPAT2 on SIN

DETD The POE-POP block copolymers are a unique class of **polymeric**  
 surfactants. The unique structure of the surfactants, with hydrophilic  
 POE and hydrophobic POP moieties in well-defined ratios and positions,  
 provides. . . Synperonic PE series (ICI); Pluronic® series  
 (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and  
 Plurodac. The generic term for these **polymers** is "poloxamer" (CAS  
 9003-11-6). These **polymers** have the formula:  
 DETD . . . use in the present invention. Preferred anionic surfactants  
 include fatty acid salts and bile salts. Specifically, preferred ionic  
 surfactants include **sodium** oleate, **sodium** lauryl sulfate, **sodium**  
 lauryl sarcosinate, **sodium** dioctyl sulfosuccinate, **sodium** cholate,  
 and **sodium** taurocholate. Examples of such surfactants are shown in  
 Table 18 below. For simplicity, typical counterions are shown in the  
 entries. . . in the art, however, that any bioacceptable counterion  
 may be used. For example, although the fatty acids are shown as **sodium**  
 salts, other cation counterions can also be used, such as alkali metal  
 cations or ammonium. Unlike typical non-ionic surfactants, these. . .

Ionic Surfactants  
COMPOUND HLB

FATTY ACID SALTS >10

**Sodium** caproate  
**Sodium** caprylate  
**Sodium** caprate  
**Sodium** laurate  
**Sodium** myristate  
**Sodium** myristolate  
**Sodium** palmitate  
**Sodium** palmitoleate  
**Sodium** oleate 18  
**Sodium** ricinoleate  
**Sodium** linoleate  
**Sodium** linolenate  
**Sodium** stearate  
**Sodium** lauryl sulfate (dodecyl) 40  
**Sodium** tetradecyl sulfate  
**Sodium** lauryl sarcosinate  
**Sodium** dioctyl sulfosuccinate [**sodium** docusate (Cytec)]

BILE SALTS >10

**Sodium** cholate  
**Sodium** taurocholate  
**Sodium** glycocholate  
**Sodium** deoxycholate  
**Sodium** taurodeoxycholate  
**Sodium** glycodeoxycholate  
**Sodium** ursodeoxycholate  
**Sodium** chenodeoxycholate  
**Sodium** taurochenodeoxycholate  
**Sodium** glyco cheno deoxycholate  
**Sodium** cholylsarcosinate  
**Sodium** N-methyl taurocholate

PHOSPHOLIPIDS

Egg/Soy lecithin [Epikuron .TM. (Lucas Meyer), Ovothin .TM. (Lucas Meyer)]  
Lyso egg/soy lecithin  
Hydroxylated lecithin  
Lysophosphatidylcholine  
Cardiolipin  
Sphingomyelin  
Phosphatidylcholine  
Phosphatidyl ethanolamine  
Phosphatidic acid  
Phosphatidyl glycerol  
Phosphatidyl serine  
PHOSPHORIC ACID ESTERS  
Diethanolammonium polyoxyethylene-10. . . fatty alcohol ethoxylates  
with phosphoric acid or anhydride  
CARBOXYLATES

Ether carboxylates (by oxidation of terminal OH group of fatty alcohol ethoxylates)  
Succinylated monoglycerides [LAMEGIN ZE (Henkel)]  
**Sodium** stearyl fumarate  
Stearoyl propylene glycol hydrogen succinate  
Mono/diacetylated tartaric acid esters of mono- and diglycerides  
Citric acid esters of mono-, diglycerides  
Glyceryl-lacto esters of fatty acids (CFR ref. 172.852)

Acyl lactylates:

lactylic esters of fatty acids  
**calcium/sodium** stearyl-2-lactylate  
**calcium/sodium** stearyl lactylate

Alginate salts

Propylene glycol alginate  
SULFATES AND SULFONATES  
Ethoxylated alkyl sulfates  
Alkyl benzene sulfones  
 $\alpha$ -olefin sulfonates

Acyl isethionates  
 Acyl taurates  
 Alkyl glyceryl ether sulfonates  
 Octyl sulfosuccinate disodium  
 Disodium undecylenamideo-MEA-sulfosuccinate  
 CATIONIC. . . .

- DETD A third method of determining optical clarity and carrier diffusivity through the aqueous boundary **layer** is to quantitatively measure the size of the particles of which the dispersion is composed. These measurements can be performed. . . .
- DETD analgesics and anti-inflammatory agents, such as aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenopropfen **calcium**, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, refocixib, sulindac, tetrahydrocannabinol, tramadol. . . .
- DETD anti-epileptics, such as beclamide, carbamazepine, clonazepam, ethotoin, felbamate, fosphenytoin **sodium**, lamotrigine, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HCl, topiramate, valproic acid, and vigabatrin;
- DETD gastrointestinal agents, such as bisacodyl, cimetidine, cisapride, daphenoxylate HCl, domperidone, famotidine, lansoprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HCl, rabeprazole **sodium**, ranitidine HCl and sulphasalazine;
- DETD muscle relaxants, such as dantrolene **sodium** and tizanidine HCl;
- DETD and others, such as becaplermin, donepezil HCl, L-thyroxine, methoxsalen, verteporfin, physostigmine, pyridostigmine, raloxifene HCl, sibutramine HCl, sildenafil citrate, tacrine, **tamsulosin** HCl, and tolterodine. . . .
- DETD . . . . a semi-solid dispersion or a solid dispersion. If desired, the compositions may be encapsulated in a hard or soft gelatin **capsule**, a starch **capsule** or an enteric coated **capsule**. The term "enteric coated **capsule**" as used herein means a **capsule** coated with a coating resistant to acid; i.e., an acid resistant enteric coating. Although solubilizers are typically used to enhance. . . . of a hydrophobic therapeutic agent, they may also render the compositions more suitable for encapsulation in hard or soft gelatin **capsules**. Thus, the use of a solubilizer such as those described above is particularly preferred in **capsule** dosage forms of the pharmaceutical compositions. If present, these solubilizers should be added in amounts sufficient to impart to the. . . .
- DETD . . . . is mono-modal and narrow. This reduced and more uniform size enables more efficient drug transport through the intestinal aqueous boundary **layer**, and through the absorptive brush border membrane. More efficient transport to absorptive sites leads to improved and more consistent absorption. . . .
- DETD . . . . conditions which limit production of lipase, such as pancreatic lipase secretory diseases; and dependence of lipolysis on stomach pH, endogenous **calcium** concentration, and presence of co-lipase or other digestion enzymes. The lack of lipolysis dependence further provides transport which does not. . . .
- DETD . . . . the pharmaceutical compositions of the present invention allow for faster transport of the hydrophobic therapeutic agent through the aqueous boundary **layer**. . . .
- DETD . . . . the hydrophobic therapeutic agent. A third solution was prepared with simulated intestinal fluid, plus an additional aliquot of 20 mM **sodium** taurocholate (a bile salt); this solution is designated SIFB in Table 29. Finally, a fourth solution was prepared with simulated intestinal fluid, 20 mM **sodium** taurocholate, and 5 mM lecithin; this solution is designated SIFBL. The 20 mM bile salt and 5 mM lecithin concentrations. . . .

DETD

Cyclosporine 0.140 g  
 Cremophor RH-40 0.41 g  
 Arlacel 186 0.29 g  
**Sodium** taurocholate 0.26 g  
 Propylene glycol 0.46 g  
 CLM What is claimed is:

. . . . lecithins; lysolecithin and hydrogenated lysolecithins;

lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; **sodium** docusate; and mixtures thereof.

CLM What is claimed is:  
. . and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; **sodium** docusate; acyl lactylates; monoacetylated tartaric acid esters of monoglycerides, monoacetylated tartaric acid esters of diglycerides, diacetylated tartaric acid esters of. . .

CLM What is claimed is:  
77. A dosage form comprising a **capsule** filled with the pharmaceutical formulation of any one of claims 69, 70, 71 or 72.

CLM What is claimed is:  
78. The dosage form of claim 77, wherein the **capsule** is a hard gelatin **capsule**, a soft gelatin **capsule**, a starch **capsule** or an enteric coated **capsule**.

CLM What is claimed is:  
88. The formulation of claim 1, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:  
95. The formulation of claim 89, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:  
105. The formulation of claim 104, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:  
107. The formulation of claim 106, wherein the formulation is contained in a **capsule**.

CLM What is claimed is:  
117. The formulation of claim 116, wherein the formulation is contained in a **capsule**.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

42.32

43.86

STN INTERNATIONAL LOGOFF AT 22:34:21 ON 13 MAR 2009